Panacos Pharmaceuticals, Inc. Share Price

Stocks

PANC

US69811Q1067

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - 15:35:13 12/11/2021 GMT 5-day change 1st Jan Change
0.000100 USD -.--% Intraday chart for Panacos Pharmaceuticals, Inc. +9,900.00% +9,900.00%
Current month+9,900.00%
1 month+9,900.00%

Valuation: Panacos Pharmaceuticals, Inc.

Market Cap 7.32M 6.65M 6.14M 5.55M 10.47M 687M 10.84M 73.86M 29.26M 369M 27.45M 26.87M 1.17B P/E 2006
-5.32x
P/E 2007 -1.12x
Enterprise Value -25.27M -22.96M -21.21M -19.16M -36.15M -2.37B -37.43M -255M -101M -1.27B -94.81M -92.81M -4.03B EV / Sales 2006
504x
EV / Sales 2007 53.9x
Free-Float
100%
Yield 2006 *
-
Yield 2007 -
1 week+9,900.00%
Current month+9,900.00%
1 month+9,900.00%
3 months+9,900.00%
6 months+9,900.00%
Current year+9,900.00%
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.01
5 years 0
Extreme 1.0E-6
0.01
10 years 0
Extreme 1.0E-6
0.04
Manager TitleAgeSince
Chief Executive Officer 69 -
Director of Finance/CFO 74 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+9,900.00%+9,900.00%+9,900.00% 53
-1.29%-3.91%+51.98%+69.06% 65.56B
-0.09%+2.79%+12.54%+95.02% 60.41B
+0.63%+1.64%+23.11%+89.70% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
+2.35%-3.61%+80.65%+60.70% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.13%-1.47%+1,022.55%+1,149.54% 40B
Weighted average by Cap. -0.27%-1.58%+35.58%+151.48%

Financials

2006 2007
Net sales 284K 258K 238K 215K 406K 26.67M 421K 2.87M 1.14M 14.31M 1.07M 1.04M 45.33M 180K 164K 151K 136K 258K 16.9M 267K 1.82M 720K 9.07M 675K 661K 28.73M
Net income -38.11M -34.62M -31.99M -28.9M -54.53M -3.58B -56.45M -385M -152M -1.92B -143M -140M -6.08B -37.46M -34.03M -31.44M -28.4M -53.6M -3.52B -55.48M -378M -150M -1.89B -141M -138M -5.98B
Net Debt -60.4M -54.88M -50.7M -45.8M -86.43M -5.67B -89.47M -610M -242M -3.04B -227M -222M -9.64B -32.58M -29.6M -27.35M -24.71M -46.62M -3.06B -48.26M -329M -130M -1.64B -122M -120M -5.2B
Logo Panacos Pharmaceuticals, Inc.
Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Employees
41
  1. Stock Market
  2. Stocks
  3. PANC Stock